FDA Approves Extended-Release Version of HIV Drug
April 6, 2011
The Food and Drug Administration has approved an extended-release form of the HIV drug nevirapine. Boehringer Ingelheim Pharmaceuticals' Viramune XR is a 400 mg tablet taken once daily; the earlier version required twice-daily dosing. "Viramune XR is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults," FDA said. Patients needing financial assistance to access the drug are asked to telephone 800-556-8317 or visit www.RxHope.com. To read FDA's statement, visit www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ucm248800.htm.
04.04.2011; Rinker Buck
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
Add Your Comment:
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)